ReviewNature medicine2017
T memory stem cells in health and disease.
Open access · greenAbstract readReview
In one paragraph
Review in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 412 papers.
0numbers the graph read from it
0cells of the map it votes in
412citing papers in PubMed
19.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
412 citing papers in PubMed, 598 citations in OpenAlex.
- BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial.Nature medicine · 2026Trial
- Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial.Nature aging · 2025Trial
- Trial
- A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.Nature communications · 2025Trial
- A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.Blood advances · 2024Trial
- In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy.Cancer immunology research · 2026Article
- Epigenetic plus cytokine therapy induces stem-like CD8Journal for immunotherapy of cancer · 2026Article
- Oral nano-delivery of a gut microbial metabolite enhances T cell stemness for cancer immunotherapy.Nature nanotechnology · 2026Article
- Epigenetic insights and innovations for overcoming barriers in CAR-T cell therapy for cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- IL-15 and IL-21 synergy improves anti-tumor efficacy of iPSC-derived cytotoxic T cells in solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Specific Biomarkers Involved in Sarcoidosis Diagnosis and Prognosis.International journal of molecular sciences · 2026Article
- Leveraging multimodal cancer immunotherapy to amplify the efficacy of oncolytic viruses.Experimental hematology & oncology · 2026Review
- Manufacturing synthetic viscoelastic antigen-presenting cells for immunotherapy.Nature protocols · 2026Review
- The T Cell Receptor: Molecular Sensor, Therapeutic Mediator and Probabilistic Driver of Adaptive Immunity.Immunological reviews · 2026Review
- Multiomic analysis identifies glutaminolysis-dependent metabolic enhancement of immune memory utilised for vaccine development.Nature communications · 2026Article
- Class I HDAC inhibition enhances the stem-like memory properties of CRISPR-engineered CAR T cells in neuroblastoma.Molecular therapy. Oncology · 2026Article
- Article
- Distinct cytokines regulate gene expression and anti-tumor activity in regenerated CD8iScience · 2026Article
- Lifestyle intervention is associated with attenuation of ER stress/inflammation and enhancement of naive immune cell identity in older adults with metabolic disease.bioRxiv : the preprint server for biology · 2026Article
352 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Luca GattinoniExperimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-2239-3282
Daniel E SpeiserDepartment of Oncology, Ludwig Cancer Research, Lausanne University Hospital, Lausanne, Switzerland.
Mathias LichterfeldDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Chiara BoniniExperimental Hematology Unit, Division of Immunology Transplantation and Infectious Diseases, Leukemia Unit, San Raffaele Scientific Institute, Milan, Italy.
Brigham and Women's Hospital · USLudwig Cancer Research · CHNational Institutes of Health · USVita-Salute San Raffaele University · IT
Funding
A Pilot Clinical Trial for HIV-1 EradicationU01AI117841 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2015 to 2020
$10.7MProgramming T Cell Fates for Therapeutic UseZIABC011480 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GATTINONI, LUCA · 2013 to 2019
$7.4MEarly Infant TreatmentU01AI114235 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2014 to 2020
$5.1MProteomics and phosphoproteomics analysis in HIV-1 infectionR01AI130005 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LICHTERFELD, MATHIAS · 2017 to 2021
$2.9MQuantification of the HIV-1 Reservoir by Immuno-PCRR01AI120008 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI HEREDIA, ALONSO, LICHTERFELD, MATHIAS · 2015 to 2019
$1.9MInhibitors of host kinases as molecular targets for immune defense against HIV-1R01AI098487 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LICHTERFELD, MATHIAS · 2012 to 2015
$1.7MPrimeFlow RNA for detection of latently-infected CD4+ T cellsR21AI124776 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI ROMERIO, FABIO · 2016 to 2017
$483kLimiting HIV-1 persistence by targeting stem cell properties of CD4 T cellsR21AI106468 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LICHTERFELD, MATHIAS · 2013 to 2014
$465kIntramural NIH HHS ZIA BC011480NIAID NIH HHS R01 AI098487NIAID NIH HHS R01 AI120008NIAID NIH HHS R01 AI130005NIAID NIH HHS R21 AI106468NIAID NIH HHS R21 AI124776NIAID NIH HHS U01 AI114235NIAID NIH HHS U01 AI117841
Abstract
T memory stem (T
Indexed as
Adoptive TransferAnimalsAutoimmune DiseasesCell DifferentiationCell Self RenewalHIV InfectionsHumansImmunologic MemoryLeukemia, T-CellStem CellsT-Lymphocytes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.